tamoxifen
FDA Approves Eli Lilly's Verzenio as Adjuvant Therapy for High-Risk, Early Breast Cancer Patients
The decision follows results from the monarchE trial, in which the drug with endocrine therapy benefited early-stage breast cancer patients with a high Ki-67 score.
Sanofi Partners With Research Groups to Study Amcenestrant in ER-Positive Breast Cancer
The global trial will compare the activity of the selective estrogen receptor degrader amcenestrant against tamoxifen in patients who cannot receive adjuvant aromatase inhibitors.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Advanced Breast Cancer Patients Benefit From Targeted, Conventional Therapy Combo, ESMO Studies Show
Premium
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.